Kelsi Vilardo
Medical · Houston, TXNPI 1407367881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 25.0% of the total. Reporting peaked in 2023 at $3,073 and has fallen 85.5% since, to $445 in 2025. Among medical clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$1K
- Amgen$1K
- UCB, Inc.$908
- Pfizer$802
- Johnson & Johnson$690
- plus $3K from 21 others
What the payments were for
- Food & beverage$10,032100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $2,513 |
| AstraZeneca(2 entities) | 48 | $1,091 |
| Amgen(2 entities) | 48 | $1,029 |
| UCB, Inc. | 43 | $908 |
| Pfizer | 38 | $802 |
| Johnson & Johnson(2 entities) | 29 | $690 |
| Novartis | 30 | $551 |
| Aurinia Pharma U.S., Inc. | 15 | $400 |
| Sanofi | 13 | $361 |
| Lilly USA, LLC | 11 | $276 |
| Mallinckrodt Hospital Products Inc. | 13 | $268 |
| E.r. Squibb & Sons, L.L.C. | 3 | $236 |
| ANI Pharmaceuticals, Inc. | 11 | $214 |
| GSK | 4 | $186 |
| Radius Health, Inc. | 5 | $126 |
| Organon | 4 | $66 |
| Sobi, Inc | 3 | $58 |
| Sandoz | 2 | $46 |
| Alvogen Inc | 2 | $44 |
| Tersera Therapeutics LLC | 1 | $37 |
| Celltrion USA Inc. | 2 | $36 |
| Octapharma USA, Inc. | 1 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Athena Bioscience, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,069 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $123,750 |
| Leflunomide | 38 | $3,064 |
| MethotrexateMethotrexate Sodium | 106 | $2,895 |
| Hydroxychloroquine Sulfate | 62 | $2,269 |
| Gabapentin | 58 | $1,114 |
| Celecoxib | 13 | $651 |
| Diclofenac Sodium | 15 | $375 |
| Methocarbamol | 13 | $269 |
| Duloxetine Hcl | 14 | $250 |
| Tramadol Hcl | 46 | $231 |
| Prednisone | 48 | $207 |
| Folic Acid | 23 | $176 |
| Cyclobenzaprine Hcl | 14 | $143 |
| Meloxicam | 21 | $105 |
| Allopurinol | 16 | $103 |
Paid to pharmacies, not to this prescriber.
Other medical in Houston
- Olga RodziyenskaHouston$65K
- Kathleen HoganHouston$26K
- Omni McCluneyHouston$18K
- Carl MayberryHouston$18K
- Carley BuddenbaumHouston$16K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.